2022 update of the indicators for quality of care and pharmaceutical care for people living with human immunodeficiency virus.

Data de publicació: Data Ahead of Print:

Autors de IIS La Fe

Autors aliens a IIS La Fe

  • Martin Conde MT
  • Navarro Aznares H
  • Robustillo Cortes MLA
  • Gonzalez, Carmen Rodriguez
  • Serrano López de Las Hazas JI
  • Morillo-Verdugo, Ramon

Abstract

OBJECTIVE: To update and define indicators for improving the quality of care and Pharmaceutical Care for people living with HIV infection in Spain. METHOD: The present project, which updates the previous version of the 2013 document, was developed in four work phases carried out between January and June 2022. In phase 1, the organization phase, a working group was created, made up of seven hospital pharmacy specialists with extensive experience in pharmaceutical care and from different SFHs in Spain. In addition, another 34 specialists participated in the evaluation of the indicators through two rounds of online evaluation to generate consensus. For phase 2, initially, a review of the identified reference literature was carried out with the aim of establishing a basis from which to define a proposal for quality criteria and indicators. Then, a preliminary proposal of criteria was made and revisions were established for their adjustment in several telematic work meetings. In phase 3, consensus was established based on the Delphi-Rand/UCLA consensus methodology. In addition, all the indicators classified as appropriate and necessary were grouped according to two levels of monitoring recommendation, so as to guide the hospital pharmacy services in the priority of their measurement: key and advanced. Finally, in phase 4, the final project document was prepared, along with the corresponding descriptive sheets for each indicator in order to facilitate the measurement and evaluation of the indicators by the hospital pharmacy services. RESULTS: Following the consensus methodology used, a list of items made up of 79 appropriate and necessary indicators was drawn up to establish a follow-up and monitoring of the quality and activity of Pharmaceutical Care for people living with HIV. Of these, 60 were established as key and 19 advanced. CONCLUSIONS: The indicators defined and updated, since the previous version of 2013, are intended to be a tool for professionals to guide decision-making and facilitate the measurement and assessment of the most relevant aspects of the quality and pharmaceutical care of people living with HIV.

Copyright © 2023. Publicado por Elsevier España, S.L.U.

Dades de la publicació

ISSN/ISSNe:
1130-6343, 0214-753X

FARMACIA HOSPITALARIA  EDITORIAL GARSI

Tipus:
Article
Pàgines:
113-120
PubMed:
37236838
Factor d'Impacte:
0,264 SCImago
Quartil:
Q3 SCImago

Documents

  • No hi ha documents

Mètriques

Filiacions mostrar / ocultar

Keywords

  • Atención Farmacéutica; Calidad; Farmacia Hospitalaria; Hiv; Hospital pharmacy; Pharmaceutical care; Quality; VIH

Projectes associats

PREVALENCIA, FACTORES ASOCIADOS Y COMPLEJIDAD FARMACOTERAPEUTICA DE LA POLIFARMACIA EN PACIENTES VIH+ EN ESPAÑA. ESTUDIO POINT.

Investigador Principal: EMILIO MONTE BOQUET

RMV-FAR-2015-01 . 2017

EVALUACIÓN DE LA USABILIDAD DE UNA APLICACIÓN MÓVIL EN PACIENTES DIAGNOSTICADOS DE MIELOMA MÚLTIPLE.

Investigador Principal: EMILIO MONTE BOQUET

SEFH-APP-MM . 2017

FACTORES PRONÓSTICO EN EL HEMANGIOMA INFANTIL.

Investigador Principal: JOSÉ LUIS POVEDA ANDRÉS

HUF-HMG-2017-01

ESTUDIO DE EVALUACIÓN EN UN ENTORNO REAL DEL USO DE AZTREONAM LISINA INHALADA EN PACIENTES CON FIBROSIS QUÍSTICA: REAZLI-FQ.

Investigador Principal: EMILIO MONTE BOQUET

AFP-AZT-2017-01 . 2018

EVALUACION DE LA CALIDAD DE VIDA RELACIONADA CON LA SALUD DURANTE EL TRATAMIENTO COMBINADO DE LA HEPATITIS CRONICA POR EL VIRUS DE LA HEPATITIS C EN CONDICIONES DE PRACTICA CLINICA HABITUAL.

Investigador Principal: EMILIO MONTE BOQUET

SCH-PEG-2007-02 . 2009

EVALUACIÓN DE LA EFECTIVIDAD DEL PLAN DE GESTIÓN DE RIESGOS PARA REVLIMID.

Investigador Principal: JAVIER DE LA RUBIA COMOS

CEL-LEN-2009-01

EFECTIVIDAD Y FACTORES PREDICTIVOS DE ABANDONO EN PACIENTES VIH PRETRATADOS EN TRATAMIENTO EN MONOTERAPIA CON LPV/R: ESTUDIO LOPIEFECT

Investigador Principal: JOSÉ LUIS POVEDA ANDRÉS

POV-LOP-2010-01

ADHERENCIA AL TRATAMIENTO ANTIBIÓTICO INHALADO DE LOS PACIENTES CON FIBROSIS QUÍSTICA. ESTUDIO I-ADHERENCIA.

Investigador Principal: AMPARO SOLÉ JOVER

GYS-COL-2011-01

INTERVENCIÓN FARMACÉUTICA PARA LA MEJORA DEL RIESGO CARDIOVASCULAR EN PACIENTES VIH EN TRATAMIENTO ANTIRRETROVIRAL ACTIVO. ESTUDIO INFAMERICA.

Investigador Principal: EMILIO MONTE BOQUET

SEF-VIH-2012-01

ESTUDIO SOBRE CUMPLIMIENTO TERAPÉUTICO EN PACIENTES CON ARTRITIS REUMATOIDE EN TRATAMIENTO CON FÁRMACOS BIOLÓGICOS DE ADMINISTRACIÓN SUBCUTÁNEA. ESTUDIO “ARCO”.

Investigador Principal: JOSÉ ANDRÉS ROMÁN IVORRA

MSD-ART-2013-01 . 2014

RIBAVIRINA ORAL PARA EL TRATAMIENTO DE INFECCIONES POR VIRUS RESPIRATORIO SINCITIAL EN PACIENTES TRASPLANTADOS DE PULMÓN.

Investigador Principal: MARÍA JESÚS CUELLAR MONREAL

MCM-RIB-2015-01

Proyecto Identity: Identificación de pacientes por biometría de voz en farmacia externa hospitalaria.

Investigador Principal: JOSÉ LUIS POVEDA ANDRÉS

BIOVOZ-2022-01 . 2023

Estudio observacional para evaluar la adherencia a TREMFYA® (guselkumab) en la práctica clínica en pacientes con psoriasis moderada a grave.

Investigador Principal: EMILIO MONTE BOQUET

CNTO1959PSO4024 . 2023

Análisis nacional de la multimorbilidad y complejidad terapéutica en receptores de trasplante de órgano sólido.

Investigador Principal: MARÍA JOSÉ FERNÁNDEZ MEGÍA

COMPLEX-TOS . 2023

Compartir la publicació